Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — Investor Presentation (August 2026)
33 slides from Cytosorbents's investor presentation, August 2026
Slide 1: Investor Presentation August 2026
NASDAQ: CTSO Investor Presentation August 2026 1 |
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation include forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our
Slide 3: Regulatory Disclaimer
Regulatory Disclaimer CytoSorb • CE Mark Approval in Europe for the following APPROVED Indications for Use: • Cytokine Removal • Bilirubin and Myoglobin Removal • Ticagrelor and Rivaroxaban removal during cardiothoracic surgery • CytoSorb is NOT yet cleared/approved by the FDA or Health Canada DrugS
Slide 4: CytoSorbents Overview
CytoSorbents Overview • U.S.-based medical device company (Nasdaq: CTSO) specializing in blood purification to treat life- threatening conditions in the intensive care unit and cardiac surgery with its proprietary, biocompatible, porous polymer bead technology CytoSorb is the first and most studied
Slide 5: The Power of the Bead
The Power of the Bead Hemocompatible, highly porous polymer bead platform technology that act like tiny sponges to remove harmful substances from blood by pore capture, adsorption, and concentration • Excellent removal of a broad range of substances from whole blood and plasma • Solid state porous p
Slide 6: Products are "Plug and Play" Compatible
Products are “Plug and Play” Compatible Compatible with Existing Blood Pump Infrastructure In Hospitals Today Dialysis or CRRT Hemoperfusion (Continuous Renal Replacement Therapy) (Standalone Treatment) ECMO CPB (Extracorporeal Membrane Oxygenation) (Cardiopulmonary Bypass) 6 | CytoSorbents Confiden
Slide 7: Four Independent Key Drivers of Value Creation
Four Independent Key Drivers of Value Creation 7
Slide 8: CytoSorb
CytoSorb Our Core Business CytoSorb is E.U. CE Mark approved but not yet cleared or approved in the U.S./Canada 8 |
Slide 9: CytoSorb is Expanding the Dimension of Blood Purification
CytoSorb is Expanding the Dimension of Blood Purification CytoSorb is a powerful blood purification technology CE-mark approved in the E.U. to reduce cytokines, bilirubin, myoglobin, and blood thinners like ticagrelor & rivaroxaban. It removes many substances that dialysis cannot. CytoSorb is design
Slide 10: Targets Deadly Conditions That Afflict Millions of People
Targets Deadly Conditions That Afflict Millions of People Critical Care Cardiothoracic Surgery Removes the “fuel to the fire” of massive Reduces inflammation and blood thinners, uncontrolled inflammation that is often targeting reduction in complications of cardiac associated with organ failure and
Slide 11: CytoSorb Has Much Larger ICU Opportunity than Dialysis
CytoSorb Has Much Larger ICU Opportunity than Dialysis Sepsis, Septic Shock, Liver Cytokine storm/ Other Shock Cytokine release Pancreatitis failure syndrome Infectious diseases Post-surgical Neuroinflammation (flu, COVID-19, other) Burn injury complications Organ transplant Acute Respiratory High r
Slide 12: CytoSorb Supported by a Wealth of Clinical Data
CytoSorb Supported by a Wealth of Clinical Data 12 |
Slide 13: The Key to Success: Right Patient, Right Timing, Right Dosing
The Key to Success: Right Patient, Right Timing, Right Dosing Right Patient Just like antibiotics, CytoSorb works most effectively when: Highest • Treat Early Chance for Good • Treat Intensively Cinical • Compete the Full Course Outcome of Treatment Right Right Timing Dose Before After Before and af
Slide 14: CytoSorb Commercialization Focus
CytoSorb Commercialization Focus • We sell CytoSorb in more than 70 countries worldwide with more than 300,000 treatments to date • Sell Direct in Germany and 9 other countries & through Distributors and partners in the remainder Estimated Revenue By Market Revenue By Geography Other Critical Care:
Slide 15: A History of Strong Annual Sales Growth
A History of Strong Annual Sales Growth Annual Product Sales $45.0 $39.5M $40.1M $40.0 $6.3 $9.4 $37.1M $35.6M $37.1 $35.0 $35.6 $33.8 $31.1M* $30.0 $29.4M* $31.1 $30.1 $29.1 $ IN MILLONS $25.0 $22.8 $20.0 $20.3 $15.0 $13.4 $10.0 $8.2 $5.0 $4.0 $0.0 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Slide 16: Progress Towards Operating Cash Flow Breakeven
Progress Towards Operating Cash Flow Breakeven ↑73% Gross Margins $9.6M 27% ~$200K Q2 2026 Revenue Operating Loss Operating Cash Burn* Improvement 38% Adjusted EBITDA Improvement 16 | * Excluding restructuring costs of ~$200K
Slide 17: Driving to Operating Cash Flow Breakeven in 2H 2026
Driving to Operating Cash Flow Breakeven in 2H 2026 Negative Free Cash Flow by Quarter (Q2 2023 - Q2 2026) Driving improved cash burn through Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 $0 efficiencies and cost reductions • $5.9 million in
Slide 18: The Opportunity of DrugSorb-ATR
The Opportunity of | DrugSorb-ATR is an investigational device that is not yet cleared/approved by FDA, Health 18 Canada, or by any other Global Regulatory Agency and is not commercially available for sale
Slide 19: Blood Thinners and Cardiac Surgery
Blood Thinners and Cardiac Surgery • Tens of millions of patients globally take Direct Oral Anticoagulants (e.g, DOACs like Eliquis® and Xarelto®) and antiplatelet agents (e.g, Brilinta®) either chronically or acutely to reduce risk of heart attack, stroke, and other serious thrombotic complications
Slide 20: Brilinta and the Use Case for DrugSorb-ATR
® Brilinta and the Use Case for 5 - 10% will need open heart surgery The ultimate goal of DrugSorb-ATR is to allow patients to get the critical surgery they need without delay while reducing or preventing X X XX X bleeding complications 20 | DrugSorb-ATR is an investigational device in the U.S. and
Slide 21: The Pivotal STAR-T RCT Paper Is Now Published
The Pivotal STAR-T RCT Paper Is Now Published • Significant 16.3% absolute reduction in major bleeding (13.7% treatment vs 30.0% control, p= 0.041) • 57.7% relative reduction in major bleeding • NNT = 6: Six patients need to be treated to prevent 1 serious bleeding event Mack, M, et al. J Thorac Car
Slide 22: FDA Regulatory Path for DrugSorb-ATR and Brilinta
FDA Regulatory Path for DrugSorb-ATR and Brilinta® Planning second De Novo Submission to FDA, where standard of approval is that: Probable Benefit Outweighs Probably Risk Targeting New De Novo Submission in Q1 2027 Potential Marketing Approval in mid-2027 To be discussed with FDA in meeting this mon
Slide 23: Meanwhile, Evidence Base for ATR Continues to Grow
Meanwhile, Evidence Base for ATR Continues to Grow • Later this month in Munich at ESC 2026 (Aug 28-31), the world’s largest CV conference, two additional analyses on antithrombotic removal in cardiac surgery will be presented: • Intraoperative ticagrelor removal to reduce bleeding after urgent CABG
Slide 24: Potential Second Shot on Goal: DOAC Removal
Potential Second Shot on Goal: DOAC Removal • Tens of millions of patients are on chronic or lifelong Direct Oral Anticoagulant (DOAC) therapy for diseases such as atrial fibrillation, DVT, pulmonary embolism, and peripheral vascular disease. Eliquis® (#7 pharmaceutical in the world with $14.4B in g
Slide 25: Large Total Addressable Market
Large Total Addressable Market Future Opportunity $1-2 Billion Near-Term Opportunity >$600M >$200M >$150M >$450M >$450M Initial Opportunity >$300M • U.S. & CAN Ticagrelor Removal in CABG • DOAC Removal in CABG • DOAC Removal in Hospital-Wide Applications • Expansion of U.S. & CAN • U.S. & CAN Ticagr
Slide 26: Unlocking the Strategic Value of HEMODEFEND-BGA
Unlocking the Strategic Value of HEMODEFEND-BGA For Universal Blood Products | HemoDefend-BGA is a preclinical device that is not yet cleared/approved by FDA, Health Canada, 26 or by any other Global Regulatory Agency and is not commercially available for sale
Slide 27: Multiple Blood Products. Millions of Units. One Compatibility Platform
Multiple Blood Products. Millions of Units. One Compatibility Platform HemoDefend is filter platform that removes anti-A and anti-B blood group antibodies that can be used across several major blood-product categories to create “Universal” products that can be given to any patient regardless of bloo
Slide 28: Simple By Design
Simple By Design GRAVITY DRIVEN Collect Platelets Filter with Universal Platelets No capital equipment or Plasma HemoDefend or Plasma Ready ~5–10 MINUTES Simple processing step SCALABLE Designed to integrate into existing blood-center workflows UNIVERSAL Low-titer, broadly compatible blood PLATFORM
Slide 29: Designed for Broad Use Across the Blood Ecosystem
Designed for Broad Use Across the Blood Ecosystem Blood Centers Hospitals Military & Emergency Plasma Processing Create more broadly Improve access to Enable easier stocking Reduce ABO antibody compatible products compatible blood and use when blood type constraints in plasma- and simplify inventory
Slide 30: HemoDefend Has Attracted Support from Leading Organizations
HemoDefend Has Attracted Support from Leading Organizations ~$16 MILLION IN NON-DILUTIVE FUNDING POSITIVE FDA ENGAGEMENT Significant external funding has supported Recent FDA written feedback supported several technical development, manufacturing, testing, and core elements of the plasma development
Slide 31: Four Independent Value Drivers. One Uncommon Value
Four Independent Value Drivers. One Uncommon Value 31 |
Slide 32: CytoSorbents Investment Thesis: Risk-Reward Asymmetry
CytoSorbents Investment Thesis: Risk-Reward Asymmetry • CytoSorbents has four largely independent paths to value creation over the next 6–18 months, each of which could be significant catalysts for upside potential 1) Achieving sustainable operating cash-flow breakeven 2) Returning the high-margin C
Slide 33: CytoSorbents
CytoSorbents NASDAQ: CTSO Company Contacts: Dr. Phillip Chan - CEO pchan@cytosorbents.com Peter Mariani – CFO pmariani@cytosorbents.com 33